Effects of fibromodulin protein expression on NFkB and TGFβ signaling pathways in liver cancer cells

authors:

avatar Sara Sadat Khatami , avatar Fatemeh Tavakoli , avatar Hossein Bagheri , avatar Reza Salarinia , avatar Amirreza Hesari , avatar Faezeh Ghasemi , *

Koomesh: Vol.22, issue 3; 529-533
article type: issue_documents_importer
received: August 01, 2019
accepted: November 02, 2019

how to cite: Khatami S S, Tavakoli F, Bagheri H, Salarinia R, Hesari A, et al. Effects of fibromodulin protein expression on NFkB and TGFβ signaling pathways in liver cancer cells. koomesh. 2020;22(3):e153210. 

Abstract

Introduction: The incidence rate of liver cancer is continuously increasing. Currently, gene therapy is applied to improve various medical issues such as cancer treatment approaches. Correspondingly, fibromodulin involves in many biological and physiological processes through interaction with growth factors and signaling pathway receptors. The aim of this study was to investigate the effects of fibromodulin gene expression on NF-kB and TGF-β signaling pathways in liver cancer cells in order to investigate the molecular pathway genes involved in this cancer. Materials and Methods: Huh-7 human liver cancer cells were cultured and the effect of fibromodulin on cell growth and proliferation was assessed using MTT assay. Then, fibromodulin gene was transfected into cells using lipofectamine and the expression of SMAD2 / 3 and TGF-β genes were investigated by Real-Time PCR method. Results: The effect of fibromodulin on TGF-β and SMAD 2/3 expression genes was evaluated in liver cancer cell line. Fibromodulin down-regulated the TGF-β and NF-kB pathways in transfected cells, compared to the control. Also, MTT results demonstrated that treatment with fibromodulin increased growth and proliferation of Huh-7 cell line in a dose-dependent manner. Conclusion: According to the results of the study, fibromodulin significantly decreased the expression levels of TGF/β and NF/kB pathway genes in liver cancer cell line. Furthermore, growth and proliferation of liver cancer cells were increased after treatment with fibromodulin. It seems that fibromodulin gene has anticancer effects on liver cancer cells.

References

  • 1.

    Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep 2019; 6: 104-111.

  • 2.

    Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 2018; 124: 2785-2800.

  • 3.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34.

  • 4.

    Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019; 156: 477-491.

  • 5.

    Endeshaw M, Hallowell BD, Razzaghi H, Senkomago V, McKenna MT, Saraiya M. Trends in liver cancer mortality in the United States: Dual burden among foreignand USborn persons. Cancer. 2019;125(5):726-34.

  • 6.

    Scheller EL, Krebsbach PH. Gene therapy: design and prospects for craniofacial regeneration. J Dent Res 2009; 88: 585-596.

  • 7.

    Dawoody Nejad L, Biglari A, Annese T, Ribatti D. Recombinant fibromodulin and decorin effects on NF-B and TGF1 in the 4T1 breast cancer cell line. Oncol Lett 2017; 13: 4475-4480.

  • 8.

    Baghy K, Ttrai P, Regs E, Kovalszky I. Proteoglycans in liver cancer. World J Gastroenterol 2016; 22: 379.

  • 9.

    Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999; 10: 303-360.

  • 10.

    Poniatowski A, Wojdasiewicz P, Gasik R, Szukiewicz D. Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediators Inflamm 2015; 2015: 137823.

  • 11.

    Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Perspectives of TGF- inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 2014; 5: 78.

  • 12.

    Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951-962.

  • 13.

    Gao J, Xu HL, Gao S, Zhang W, Tan YT, Rothman N, et al. Genetic polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: a nested casecontrol study in Shanghai, China. BMJ Open 2014; 4: e004427.

  • 14.

    Xia Y, Shen S, Verma IM. NF-B, an active player in human cancers. Cancer Immunol Res 2014; 2: 823-830.

  • 15.

    Park MH, Hong JT. Roles of NF-B in cancer and inflammatory diseases and their therapeutic approaches. Cells 2016; 5.

  • 16.

    Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.

  • 17.

    Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology 2013; 2: e26468.

  • 18.

    Pourhanifeh MH, Mohammadi R, Noruzi S, Hosseini SA, Fanoudi S, Mohamadi Y, et al. The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer Cell Int 2019; 19: 157.

  • 19.

    Mormone E, Lu Y, Ge X, Fiel MI, Nieto N. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. Gastroenterology 2012; 142: 612-621.e5.

  • 20.

    Baghy K, Ttrai P, Regs E, Kovalszky I. Proteoglycans in liver cancer. World J Gastroenterol 2016; 22: 379-393.

  • 21.

    Morn A, Bellomo C, Tsubakihara Y, Kardassis D, Mikulits W, Heldin CH, Moustakas A. LXR limits TGF-dependent hepatocellular carcinoma associated fibroblast differentiation. Oncogenesis 2019; 8: 36.

  • 22.

    Jia M, Souchelnytskyi S. Comments on the cross-talk of TGF and EGF in cancer. Exp Oncol 2011; 33: 170-173.

  • 23.

    Luedde T, Schwabe RF. NF-B in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118.

  • 24.

    Lee YH, Schiemann WP. Fibromodulin suppresses nuclear factor-b activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis. J Biol Chem 2011; 286: 6414-6422.

  • 25.

    Jazi MF, Biglari A, Mazloomzadeh S, Kingston P, Ramazani A, Bazzaz JT, Eskandari M. Recombinant fibromodulin has therapeutic effects on diabetic nephropathy by down-regulating transforming growth factor-1 in streptozotocin-induced diabetic rat model. Iran J Basic Med Sci 2016; 19: 265-271.